Research Article

Open Access

Contribution of Gene-Xpert in the Diagnosis of Negative Microscopy Pulmonary Tuberculosis in Brazzaville, Republic Of Congo

Laure Stella Ghoma Linguissi^{1*}, Clément Armand Nyanga-Koumou², Christ Eya¹

¹ Department of Public Health, National Institute for Research in Health Sciences (IRSSA), Brazzaville, Republic Of Congo

² Medical Biology Laboratory Central Army Hospital, Pierre Mobengo, Brazzaville, Republic Of Congo

Abstract

Setting:

Xpert MTB/Rif has become an integral part of tuberculosis diagnostic algorithms in many low- and middle-income countries and no published data was retrieved regarding the diagnostic accuracy of Xpert MTB/RIF in sputum smear-negative pulmonary TB in RoC.

Objectives:

This study aimed at determining the diagnostic accuracy of Xpert MTB/RIF in diagnosing sputum smear-negative pulmonary tuberculosis keeping AFB microscopy as the gold standard.

Design:

For 4 months, one morning sputum smear was performed for every TB suspect (cough lasting >3 weeks, as defined in Congolese's national guidelines) with AFB microscopy and GeneXpert.

Results:

Of 90 TB suspects for whom AFB microscopy and GeneXpert were performed, 79 (87.78%) sputum smear-negative 17 (21.52%) GeneXpert positive cases were identified. During the study, 11 (12.22%) sputum smear-positive cases were diagnosed. GeneXpert has greatly contributed to increasing the total number of bacteriologically proven cases.

Conclusion:

These results confirms the utility of GeneXpert in the diagnosis of tuberculosis especially smear negative pulmonary tuberculosis, and demonstrates that the expected number of smear-negative TB cases in Republic of Congo is probably much higher than the World Health Organization's current annual estimates.

Corresponding author: Laure Stella Ghoma Linguiss, Department of Public Health, National Institute for Research in Health Sciences (IRSSA), Brazzaville, Email: linguissi@gmail.com / irssacongo.ur4@gmail.com

Received: February22, 2020; **Accepted:** March 07, 2020; **Published:** March 13, 2020;

Keywords: Pulmonary Tuberculosis, Sputum Smear Negative, Xpert MTB/RIF, Multidrug-Resistant, Brazzaville

Introduction

Republic of Congo, with these 5.2 million inhabitants, has low access to pulmonary tuberculosis diagnosis, with a rate of mortality of 57 (32–89) per 100,000 inhabitants due to TB occur [1]. Sputum smear examination is the mainstay of pulmonary TB diagnosis [2]. In a few studies performed in Brazzaville, there is a higher proportion of bacteriologically-confirmed TB, a shorter time to treatment initiation [3,4]. For several years, the diagnosis of pulmonary tuberculosis is done through clinical signs, results from sputum smear microscopy, tuberculin skin test and X-ray chest [2].

According to the National Tuberculosis Control Program, 11,512 cases of all forms of tuberculosis were detected in 2012, of which 4,465 cases of pulmonary tuberculosis with smear sputum positive microscopy, 39%, 3,937 cases of pulmonary tuberculosis with smear sputum negative microscopy [5]. A positive smear signifies a very large bacterial population in the lung lesions whereas several negative smears suggest a smaller bacterial load [6,7]. Such smear-negative cases do not require the same intensity and duration of treatment as smear-positive cases. Diagnostic difficulties arise when sputum smears are negative for acid-fast bacilli in tuberculin-positive patients with compatible symptoms and chest radiographs for tuberculosis. Microscopy requires approximately 5,000 to 10,000 AFB/ml of sputum for detection [8]. Many of these smear-negative patients yield positive cultures for M tuberculosis, whereas others remain culturally negative.

The eligibility criteria for the GeneXpert test are set up such that only the cases of the patients in therapeutic failure are diagnosed with this new molecular tool, because of reagents in reduced number [9]. Studies have consistently shown that Xpert MTB/RIF can identify a substantial proportion of smear-negative TB patients and extrapulmonary TB, particularly in people co-infected with human immunodeficiency virus [10-12].

Drug-resistant TB care, the number of MDR/RR-TB cases among notified pulmonary TB cases estimated 290. Globally, there were an estimated 2.4% of new cases and 12% of previously treated cases with MDR/RR-TB. All of cases previously treated were tested for rifampicin resistance and only 15% of cases were primary resistances [1].

To improve patient care and decrease TB transmission, accurate and quick detection of TB especially smear negative

and TB drug resistance is essential [13]. Xpert can serve as a time-saving diagnostic method for microbiological diagnosis of smear-negative TB in countries with a low TB prevalence [14].

In national TB programs, low bacillary load pulmonary tuberculosis is of little interest because of its low risk of contamination. However, clinically, it is a concern due to the prognostic importance of anti-tuberculosis treatment. Improving the diagnostic accuracy and reducing diagnostic delay in both smear-negative pulmonary tuberculosis is therefore paramount [14,15]. Also, the diagnosis of smear-negative pulmonary tuberculosis still represents a challenge, due to its paucibacillary nature leading to a prolonged time before the diagnosis occur [14]. Xpert MTB/Rif has become an integral part of tuberculosis diagnostic algorithms in many low- and middle-income countries and no published data was retrieved regarding the diagnostic accuracy of Xpert MTB/RIF in sputum smear-negative pulmonary TB in RoC. This study thus aimed at determining the diagnostic accuracy of Xpert MTB/RIF in diagnosing sputum smear-negative pulmonary tuberculosis keeping AFB microscopy as the gold standard.

Material and methods

A descriptive, analytical study was conducted from July to November 2019, during 4 months, at the military hospital, in Brazzaville. This research study conducted on 79 sputum specimens from bacteriologically confirmed cases sputum smear negative. These patients came from Brazzaville. These patients were initially screened for TB through AFB sputum smear microscopy at medical laboratory of the military hospital. All the AFB smear-negative patients with persistent clinical symptoms of TB were referred to the confirmation of test GeneXpert MTB/RIF assay.

Before specimen collection, the patients were informed about the study and written consent was obtained. The patients were asked to collect the sputum specimens following the standard sputum collection technique using the recommended sterile plastic (50-mL Tarson) containers. One half of the collected sputum specimen was used for AFB sputum smear microscopy, while the remaining portion was used for GeneXpert MTB/RIF assay. The research study was conducted following the approved guidelines framed by the research scrutiny committee of the Institut National de Recherche en Science de la Santé (IRSSA).

Ziehl-Neelsen staining and the Xpert test was performed according to the manufacturer's recommendations. With

phased introduction of Xpert to replace sputum smears as the initial diagnostic test for new pulmonary TB [16]. In the smear microscopy, up to two sputum smears per patient were examined by conventional optic microscopy based on direct Ziehl-Neelsen staining, as per routine [17].

Direct smears were prepared for microscopic examination of AFB by applying one drop of sputum samples on a clean glass slide which was labeled with the ID number. The smear was air dried followed by heat fixation and staining using ZN staining methods [18]. The stained smears were examined microscopically using 100× objective lens. Control slides (known positive and known negative) were included as procedural control with each run of ZN staining.

In the Xpert, usually only one of the submitted samples was examined within two days of being received by the laboratory. To 2 mL of sample reagent, 1 mL of sputum specimen was added and the sputum specimen was allowed to liquefy for 15 min. using a sterile dropper provided with the kit, 2 mL of mixture was transferred into the GeneXpert cartridge. This cartridge contained the required reagents for nucleic acid amplification and RIF drug resistance detection. The inoculated cartridge was loaded into the GeneXpert machine. Results were displayed by the GeneXpert system automatically within 2 h. The operator can read and print the test results as “MTB detected; RIF resistance not detected.” Confirmed bacteriological TB was defined as a positive Xpert result.

1/2 3.0(STANDARD DIAGNOSTICS, Republic of Korea) and Test Uni-Gold™ HIV (TRINITY BIOTECH PLC Ireland) have been used successively for HIV testing. All samples were prepared following the manufacturer instructions.

Ethical clearance was obtained from the CERSSA, institutional ethics committee de l’Institut National de Recherche en Science de la Santé (IRSSA) (No. 00000067/DGRST/CERSSA).

Statistical Analysis

We used Epi info 7.2.2 software for the statistical analysis. The P-value of less than 0.05 was considered to indicate statistical significance.

Results

A total of 90 M. tuberculosis-presumptive patients were included in the study (Figure 1). The majority of the study participants were males 69 (76.67%). The mean age was 38.9 ± 12.7 . The median was 38 years, the maximum age was 81 years and the minimum of 15 years. Most of the subjects (86.67%) were under >25 years of age.

The microscopic results were represented as follows: 11 (12.22%) had a high bacillary load compared to 79 (87.78%) with a low bacillary load. The overall prevalence of M. tuberculosis-confirmed cases was 26.67%. Of the 24 (26.67%) M. tuberculosis-confirmed cases, 4 (4.44%, 95% CI 1.22-10.99) were resistant to rifampicin. Rifampicin-resistant M. tuberculosis was observed among HIV seropositive 2 (50%), males 2 (50%), and previously treated tuberculosis patients 2 (50%), although no significant association was found in this study.

Of the 90 individuals, the microscopic results were represented by 11 (12.22%) individuals with a high bacillary load against 79 (87.78%) with a low bacillary load. The GeneXpert technique detected 24 (26.67%) cases of positive GeneXpert showing the presence of Mycobacterium tuberculosis against 66 (73.33%) who did not have mycobacteria. Table 1 This table shows that the cases of chronic cough 17 (45.95%) were more important among the positive cases of GeneXpert.

Table 2 This table shows that the cases of cough 52 (68.42%) were more important among the positive cases of GeneXpert.

Figure 1: Study algorithm

Figure 1: Study Algorithm.

HIV testing

All blood samples were tested by the same kit manufactured by the same company. Three rapid tests, Determine HIV 1/2 test (Alere GmbH, Koln, Germany), Test SD BIOLINE HIV-

Variables	AFB-	AFB+	P-value
Demographic characteristic			
Male n (%)	63 (79.75%)	6 (54.55%)	0.1
Symptoms			
Cough	65 (82.28%)	11 (100%)	0.2
Type of cough			
Aigue	37 (56.92%)	2 (43.08%)	0.02
Chronic	28 (18.18%)	9 (81.82%)	
Duration cough			
<2 Weeks	30 (46.15%)	0 (0%)	0.002
>2 Weeks	35 (53.85%)	11 (100%)	
Comorbidities			
HIV	17 (21.52%)	3 (27.27%)	0.7

Table 1: Distribution of microscopic results.

Variables	GeneXpert -	GeneXpert+	P-value
Demographic characteristic			
Male n (%)	48 (77.42%)	21 (75%)	0.7
Symptoms			
Cough	49 (79.03%)	27 (96.43%)	0.055
Type of cough			
Aigue	30 (61.22%)	9 (33.33%)	0.03
Chronic	19 (38.78%)	18 (66.67%)	
Duration cough			
<2 Weeks	27 (55,10%)	3 (11,11%)	0.0001
>2 Weeks	22 (44,90%)	24 (88,89%)	
Comorbidities			
HIV	12 (60%)	8 (40%)	8 (40%)

Table 2: Distribution of GeneXpert results.

AFB and GeneXpert diagnostic

All sputum samples were processed for smear microscopy to confirm smear negativity for AFB and found negative by ZN staining method. The sputum samples were further processed for GeneXpert MTB/RIF assay. A known AFB-pos-

itive specimen and AFB-negative specimens were also included to serve as controls for validation of the ZN staining protocol. A total of 90 sputum specimens from suspected TB patients were tested for tuberculosis by AFB test, GeneXpert. 48 (18.39%) cases were detected by AFB test and 62 (23.76%) by GeneXpert.

The type of cough, whether acute or chronic, was associated with AFB - ($p = 0.02$). The duration of cough corresponding to less than 2 weeks was associated with the results of AFB -, while when the duration exceeded 2 weeks was associated with AFB + ($p = 0.002$). The type of cough, whether acute or chronic, was associated with a Genexpert - ($p = 0.03$). The duration of cough corresponding to less than 2 weeks was associated with the results of GeneXpert -, while when the duration exceeded 2 weeks was associated with Genexpert + ($p = 0.0001$).

Discussion

In this study, sputum specimens from presumptive TB cases from Brazzaville were investigated to evaluate the efficiency of GeneXpert MTB/RIF assay against screened conventional ZN staining smear-negative results. Rasool et al, reported that approximately 17% of TB disease transmission is caused by AFB smear microscopy-negative TB suspects and therefore the risk of disease transmission by AFB-negative cases to healthy individuals could not be ignored [19].

In Republic of Congo, the diagnosis of pulmonary tuberculosis remains a public health problem in our country, especially in immunocompromised subjects [20,21]. A study carried out in Brazzaville, at the Tuberculosis Center revealed that the eligibility criteria were set up in such a way that only cases of patients with therapeutic failure were diagnosed with this new molecular tool, because of reagents in reduced numbers [9]. A selection of patients based on the risk analysis could allow a rational use of this test. However, this does not take into account bacteriologically confirmed smear negative cases, which may prove to be geneXpert positive. In addition, resistance to rifampicin is a good predictor of multi resistance. The presence of primary resistance in the population suspected of pulmonary tuberculosis is important in our country (2.4%).

Smear-negative pulmonary TB patients (SNPT) represents between 30% and 60% of all pulmonary TB cases (Luo et al., 2017) and 10–20% of TB transmission at the population level

are attributable to SNPT cases [22]. In addition, the high frequencies of Smear-negative pulmonary TB patients are observed in countries with a high prevalence of HIV infection [23,24]. HIV co-infection, is seen as both a risk factor and an aggravating factor [25]. Of the 90 individuals, the microscopic results were represented as follows: 11 (12.22%) had a high bacillary load against 79 (87.78%) had a low bacillary load. On the other hand, GeneXpert has detected *Mycobacterium tuberculosis*, the pathogenic agent which confers pulmonary tuberculosis in 24 individuals, ie 26.67%. Okonkwo et al., In a similar study, found a prevalence of 19.8% of MTB detected [26]. This higher prevalence is certainly due to the fact that our study took place in a hospital setting where a high concentration of individuals showing suspected pulmonary tuberculosis is found.

The prevalence of HIV in people with pulmonary tuberculosis was 22.47%. Dagnra et al. revealed in 2010, among 569 patients, 135 (23.7%) were infected with HIV. *Mycobacterium tuberculosis* co-infection is the leading cause of death in people infected with HIV-1. The increase in drug-resistant tuberculosis threatens the global fight against tuberculosis and constitutes a major public health problem [27]. Okemba-Okombi et al. in their study at the Brazzaville Tuberculosis Center observed cases of resistance to Rifampicin (18.02%) [9].

Xpert could greatly reduce the frequency and impact of unnecessary empiric treatment, contact investigation, and housing, providing substantial patient and programmatic benefits if used in management decisions. This is the first study to demonstrate the potential of GeneXpert M. tuberculosis/rifampicin to increase case findings, identify drug resistance, and guide treatment of TB in Brazzaville. There is benefit of Gene-Xpert testing in difficult to diagnose patient with sputum smear negative pulmonary tuberculosis. GeneXpert test potentially limit loss to follow up during diagnostic evaluation of smear negative tuberculosis patients.

AFB smear-negative cases found to have delays in treatment initiation, and especially that there are more and more false negative cases which are detected positive by molecular biology or culture. The GeneXpert MTB/RIF assay (Xpert) must be a novel automated diagnostic tool for tuberculosis and its optimal placement in the healthcare system must be fine determined. There is possibility of additional case detection for pulmonary tuberculosis by offering Xpert to smear-negative patients. Patients routinely presenting with symptoms sug-

gestive of PTB with negative smears can thus benefit from the Xpert test which increase pulmonary TB case confirmation. GeneXpert could use for rapid and accurate diagnosis of TB in Republic of Congo, country where TB endemic settings. This will help to detect cases that may have been missed by AFB test and since GeneXpert could detect RR-TB, early enhance patient treatment and management.

Chronic cough was associated with the presence of *Mycobacterium tuberculosis* ($p = 0.01$). This has been widely described in several studies of pulmonary tuberculosis [28-30]. The presence of cough during the clinical examination was also associated with the presence of *Mycobacterium tuberculosis* ($p = 0.01$). Cough is a risk factor for pulmonary tuberculosis and chronic cough is significantly linked to the detection of *Mycobacterium tuberculosis* [30-32].

The prevalence of HIV in people with pulmonary tuberculosis was 22.47%. *Mycobacterium tuberculosis* co-infection is the leading cause of death in people infected with HIV-1. In our study, HIV status was not associated with the detection of AFB- ($p = 0.7$). Rates of smear-negative pulmonary have been rising in countries with HIV epidemics. The mortality rate among HIV-infected tuberculosis patients is higher than that of uninfected tuberculosis patients, particularly for those with smear-negative pulmonary. Delayed diagnosis may be an important cause of excess mortality in people living with HIV who have smear-negative pulmonary. In the absence of rapid, simple, and accurate diagnostic tools for smear-negative pulmonary, diagnostic algorithms could be recommended.

Conclusion

Early diagnosis of pulmonary tuberculosis in smear negative pulmonary TB suspects is critical for early initiation of therapy. In our Country, GeneXpert assay should be used as a gold standard to diagnose all TB forms. Smear-negative TB represents a large proportion of TB cases in the Republic of Congo, and occurs more often among persons in groups more likely to undergo TB screening. The lower mortality may indicate earlier TB detection, and underscores the need for continued vigilance in screening of high-risk persons. Our study confirms the utility of GeneXpert in the diagnosis of tuberculosis especially smear negative pulmonary tuberculosis.

Acknowledgements

The authors would like to acknowledge Pierre Mobengo hospital in Brazzaville city-Republic of Congo for support and provided working space and materials.

Availability of data and materials

All the data are already found in the manuscript and there are no supplementary files. The original data supporting this finding will be available at any time upon request of the corresponding author.

Disclosure Statement

Authors have seen and approved the manuscript being submitted and there is no conflict of interest. We warrant that the article is the Authors' original work. This research has not been submitted for publication nor has it been published in whole or in part elsewhere. Authors listed on the title page have contributed significantly to the work, have read the manuscript, attest to the validity and legitimacy of the data and its interpretation, and agree to its submission to the Journal for publication

Notes

Ethics approval and consent to participate

The study was conducted in accordance with the ethical standards of the Helsinki Declaration of 1975, as revised in 2000. This study was reviewed and approved by the Comité éthique de la Recherche en Sciences de la Santé (CERSSA). Since this was a research study, written informed consent was requested for study participation from every participant. None of the data can be linked to individuals and no patient identifiers were used. Confidentiality of the information collected was maintained by omitting their name and other personal identifiers from extraction sheet. The study did not require collection of additional patient samples or performance of any test additional to routine patient care procedures so the study did not constitute a risk for the patients. The study was conducted inside an ongoing research project aiming at the development of a comprehensive clinical approach towards the diagnosis of pulmonary tuberculosis in Republic of Congo.

Consent for publication

Not applicable.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper. There are no conflicts of interest of any kind, including any relationship or dual interest, financial or otherwise, that may affect professional judgment in relation to this article.

References

1. WHO (2019) Tuberculosis profile - Congo.
2. Linguissi LSG, Vouvongui CJ, Poulain P, Essassa GB, Kwedi S, Ntouni F(2015) Diagnosis of smear-negative pulmonary tuberculosis based on clinical signs in the Republic of Congo. *BMC Res* 18(8): 804.
3. Emba ELP, Horo K, Okemba Okombi FH, Ossale Abacka KB, Ouedraogo AR, et al. (2015) Influence of the course of care on the time to initiation of tuberculosis treatment. *Rev. Pneumol. Clin* 71: 226–232.
4. Ossibi Ibara BR (2017) Epidemiological Features and Associated Factors of Pulmonary Tuberculosis with Positive Microscopy in the Infectious Diseases Unit at the CHU of Brazzaville. *J. Lung Pulm. Respir. Res.* 4(5): eISSN: 2376-0060
5. Ministry of Health and Population, 2014. 2015-2016 Biennial Health Development Program.
6. Gangadharam PRJ, Jenkins PA (Eds.) (1998) *Mycobacteria*. Springer US, Boston, MA 1-436.
7. Schlossberg D (Ed.) (2015) *Clinical infectious disease*, Second edition. ed, Cambridge medicine. Cambridge University Press, Cambridge, United Kingdom.
8. Parsons LM, Somoskovi A, Gutierrez C, Lee E, Paramasivan CN, Abimiku A, et al. (2011) Laboratory Diagnosis of Tuberculosis in Resource-Poor Countries: Challenges and Opportunities. *Clin. Microbiol. Rev* 24: 314-350.
9. Okemba-Okombi FH, Itoua A, Biniakounou JB, Illoye-Ayet M, ELP Bemba, et al. (2015) Apport du GeneXpert dans le diagnostic de la tuberculose pulmonaire : étude préliminaire et perspectives en République du Congo. *Elsevier Rev. Mal. Respir* 32 : A211.
10. Horne, D.J., Kohli, M., Zifodya, J.S., Schiller, I., Dendukuri, N., Tollefson, D., Schumacher, S.G., Ochodo, E.A., Pai, M., Steingart, K.R., 2019. Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults. *Cochrane Database Syst. Rev.* <https://doi.org/10.1002/14651858.CD009593.pub4>
11. Kohli M, Schiller I, Dendukuri N, Dheda K, Den-

- kingier CM, et al. (2018) Xpert ® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance. *Cochrane Database Syst. Rev.* <https://doi.org/10.1002/14651858.CD012768.pub2>
12. Meyer AJ, Atuheire C, Worodria W, Kizito S, Katamba A, et al. (2017) Sputum quality and diagnostic performance of GeneXpert MTB/RIF among smear-negative adults with presumed tuberculosis in Uganda. *PloS One* 12 : e0180572.
13. Rasheed, W., Rao, N.A., Adel, H., Baig, M.S., Adil, S.O., 2019. Diagnostic Accuracy of Xpert MTB/RIF in Sputum Smear-Negative Pulmonary Tuberculosis. *Cureus*. <https://doi.org/10.7759/cureus.5391>
14. Lombardi, G., Di Gregori, V., Girometti, N., Tadolini, M., Bisognin, F., Dal Monte, P., 2017. Diagnosis of smear-negative tuberculosis is greatly improved by Xpert MTB/RIF. *PLOS ONE* 12, e0176186. <https://doi.org/10.1371/journal.pone.0176186>
15. Chikaonda, T., Nguluwe, N., Barnett, B., Gokhale, R.H., Krysiak, R., Thengolose, I., Rosenberg, N.E., Stanley, C., Mpunga, J., Hoffman, I.F., Hosseinipour, M., Scott, L., Stevens, W., 2017. Performance of Xpert® MTB/RIF among tuberculosis outpatients in Lilongwe, Malawi. *Afr. J. Lab. Med.* 6, 7 pages. <https://doi.org/10.4102/ajlm.v6i2.464>
16. Kik, S.V., Denking, C.M., Chedore, P., Pai, M., 2014. Replacing smear microscopy for the diagnosis of tuberculosis: what is the market potential? *Eur. Respir. J.* 43, 1793–1796. <https://doi.org/10.1183/09031936.00217313>
17. Zingue, D., Weber, P., Soltani, F., Raoult, D., Drancourt, M., 2018. Automatic microscopic detection of mycobacteria in sputum: a proof-of-concept. *Sci. Rep.* 8, 11308. <https://doi.org/10.1038/s41598-018-29660-8>
18. Khanna, V., Tilak, K., Ghosh, A., Mukhopadhyay, C., 2014. Modified Negative Staining of Heine for Fast and Inexpensive Screening of *Cryptosporidium*, *Cyclospora*, and *Cystoisospora* spp. *Int. Sch. Res. Not.* 2014, 1–4. <https://doi.org/10.1155/2014/165424>
19. Rasool, G., Khan, A.M., Mohy-Ud-Din, R., Riaz, M., 2019. Detection of *Mycobacterium tuberculosis* in AFB smear-negative sputum specimens through MTB culture and GeneXpert ® MTB/RIF assay. *Int. J. Immunopathol. Pharmacol.* 33, 205873841982717. <https://doi.org/10.1177/2058738419827174>
20. Linguissi, L.S.G., Gwom, L.C., Nkenfou, C.N., Bates, M., Petersen, E., Zumla, A., Ntoumi, F., 2017. Health systems in the Republic of Congo: challenges and opportunities for implementing tuberculosis and HIV collaborative service, research, and training activities. *Int. J. Infect. Dis.* 56, 62–67. <https://doi.org/10.1016/j.ijid.2016.10.012>
21. Ossibi Ibara, B., Okemba-Okombi, F., Obengui, Mbemba Esther, L., Boumandouki, J., Ogame Ontsi, F., Puruehnce, M., 2016. Associated pulmonary tuberculosis in HIV patients in Department of Infectious Diseases of the University Hospital of Brazzaville: Prevalence and Associated factors. *J. Funct. Vent. Pulmonol.* 7, 24–28. <https://doi.org/10.12699/jfvp.7.20.2016.24>
22. Campos, L.C., Rocha, M.V.V., Willers, D.M.C., Silva, D.R., 2016. Characteristics of Patients with Smear-Negative Pulmonary Tuberculosis (TB) in a Region with High TB and HIV Prevalence. *PLOS ONE* 11, e0147933. <https://doi.org/10.1371/journal.pone.0147933>
23. Osei, E., Der, J., Owusu, R., Kofie, P., Axame, W.K., 2017. The burden of HIV on Tuberculosis patients in the Volta region of Ghana from 2012 to 2015: implication for Tuberculosis control. *BMC Infect. Dis.* 17, 504. <https://doi.org/10.1186/s12879-017-2598-z>
24. Sinshaw, W., Kebede, A., Bitew, A., Tesfaye, E., Tadesse, M., Mehamed, Z., Yenew, B., Amare, M., Dagne, B., Diriba, G., Alemu, A., Getahun, M., Fikadu, D., Desta, K., Tola, H.H., 2019. Prevalence of tuberculosis, multidrug resistant tuberculosis and associated risk factors among smear negative presumptive pulmonary tuberculosis patients in Addis Ababa, Ethiopia. *BMC Infect. Dis.* 19, 641. <https://doi.org/10.1186/s12879-019-4241-7>
25. Bruchfeld, J., Correia-Neves, M., Källénus, G., 2015. Tuberculosis and HIV Coinfection. *Cold Spring Harb. Perspect. Med.* 5, a017871. <https://doi.org/10.1101/cshperspect.a017871>
26. Okonkwo Rc, Onwunzo Mc, Chukwuka Cp, Ele Pu, Anyabolu Ae, Ca, O., Mo, I., Cn, A., E, E., Kc, O., 2017. The Use of the Gene Xpert *Mycobacterium tuberculosis*/Rifampicin (MTB/Rif) Assay in Detection of Multi-Drug Resistant Tuberculosis (MDRTB) in Nnamdi Azikiwe University Teaching Hospital, Nnewi, Nigeria. *J. HIV Retro Virus* 03. <https://doi.org/10.21767/2471-9676.100028>
27. Trinh QM, Nguyen HL, Nguyen VN, Nguyen TVA, Sintchenko V, Marais BJ (2015) Tuberculosis and HIV co-infection—focus on the Asia-Pacific region. *Int. J. Infect. Dis* 32: 170–178.
28. Ones-López EC, Kim S, Fregona G, Marques-Rodrigues P, Hadad DJ, et al. (2014) Importance of Cough and *M. tuberculosis* Strain Type as Risks for Increased Transmission within Households. *PLoS ONE* 9: e100984.
29. Lee S, Lau L, Lim K, Ferma J, Dodd W, Cole D (2019) The Presence of Cough and Tuberculosis: Active Case Finding Outcomes in the Philippines. *Tuberc. Res. Treat*

- 1–9.
30. 30. Patterson B, Wood R (2019) Is cough really necessary for TB transmission? Tuberculosis 117: 31-35.
31. 31. Proaño A, Bravard MA, López JW, Lee GO, Bui D, et al. (2017) Dynamics of Cough Frequency in Adults Undergoing Treatment for Pulmonary Tuberculosis. Clin. Infect. Dis 64: 1174–1181.
32. 32. Zingue D, Weber P, Soltani F, Raoult D, Drancourt M (2018) Automatic microscopic detection of mycobacteria in sputum: a proof-of-concept. Sci. Rep 8: 11308. <https://doi.org/10.1038/s41598-018-29660-8>

Copyright: ©2020 Linguissi L. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.